乳腺癌患者外周血表皮生长因子受体mRNA与组织中蛋白表达的相关性及其意义

 目的 本研究旨在检测乳腺癌患者外周血EGFRmRNA的表达，评价其作为循环乳腺癌细胞标志的可能性；结合相应肿瘤组织中EGFR蛋白的检测，分析两者的相关性；并结合临床病理资料综合分析，探讨其在乳腺癌患者外周血中表达的意义。方法 以RT-PCR法，分别对40例乳腺癌患者、25例良性乳腺病患者和30例健康人外用静脉血进行EGFRmRNA检测。免疫组化法检测相应肿瘤组织中EGFR蛋白的表达情况。结果 乳腺癌组外周静脉血中EGFRmRNA检出率（32．5％）与健康人组（0）和良性乳腺病患者组（0）间差异均存在统计学意义（P〈0．01）。免疫组化法检测到乳腺癌患者相应肿瘤组织中有25例（62．5％）EGFR蛋白阳性，组织中EGFR蛋白表达级别高的患者其相应外周血EG—FRmRNA的检出率也高。EGFRmRNA阳性表达与临床分期、组织学分级及ER闰存在明显的相关性，而与病理类型、肿瘤大小、腋窝淋巴结转移、PR和HER-2间无明显相关性。结论 RT-PCR法检测乳腺癌患者外周血EGFRmRNA有望成为检测循环乳腺癌细胞的有效方法。结合临床病理资料分析，RT—PCR法检测外周血EGFRmRNA有助于判断乳腺癌的预后，有益于乳腺癌微转移的早期诊断、治疗方案的选择及治疗疗效的监测。

Expression of EGFR mRNA Gene in Peripheral Blood of Breast Cancer Patients and EGFR Protein in Corresponding Tumor Tissues and Its Clinical Significance

Objective To evaluate the feasibility of detecting EGFR mRNA by RT-PCR in peripheral blood of patients with breast cancer,to explore the relationship between EGFR mRNA in peripheral blood and EGFR protein in corresponding tumor tissues and to explore its clinical significance.Methods RT-PCR assay was applied to detect the expression of EGFR mRNA in the peripheral blood of 40 patients with breast cancer, 25 patients with benign breast diseases and 30 healthy donors. Expression of EGFR protein in corresponding tumor tissues was detected by immunohistochemistry. Results EGFR mRNA was expressed in 13 of 40(32.5%) patients with breast cancer,compared with both healthy donors (0%)and benign breast disease patients(0%) (P<0.01). On the other hand,expression of EGFR protein in corresponding tumor tissues was detected in 25(62.5%) of 40 breast cancer patients by immunohistochemistry. Patients with high expression grade of EGFR protein displayed high expression rate of EGFR mRNA in peripheral blood as well. The expression of EGFR gene was significantly correlated with clinical stage, histological grading and ER, but had no coincidence with pathologic type, tumor size, lymph node metastasis,PR and HER-2.Conclusion Detection of EGFR mRNA in peripheral blood by RT-PCR may be an effective method of detecting CTCs in breast cancers. It may be used as a prognostic indicator and may also contribute significantly to early diagnosis of micrometastasis,the decision on therapies and evaluation of treatment effect.